Collectively, these findings represent an alternative to tyrosine kinase activity for the oncoprotein and leukemogenic cells and generate a rationale of targeting RAPSYN-mediated BCR-ABL neddylation for the treatment of Ph<sup>+</sup> leukemia. This evidence concerns the gene ABL1 and leukemia.